81 related articles for article (PubMed ID: 20400170)
1. Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies.
Zhou N; Fan L; Ho HT; Nowicka-Sans B; Sun Y; Zhu Y; Hu Y; McAuliffe B; Rose B; Fang H; Wang T; Kadow J; Krystal M; Alexander L; Colonno R; Lin PF
Virology; 2010 Jul; 402(2):256-61. PubMed ID: 20400170
[TBL] [Abstract][Full Text] [Related]
2. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
[TBL] [Abstract][Full Text] [Related]
3. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
[TBL] [Abstract][Full Text] [Related]
4. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.
Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H
Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340
[TBL] [Abstract][Full Text] [Related]
5. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
[TBL] [Abstract][Full Text] [Related]
6. Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes.
Franquelim HG; Chiantia S; Veiga AS; Santos NC; Schwille P; Castanho MA
AIDS; 2011 Feb; 25(4):419-28. PubMed ID: 21245727
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
[TBL] [Abstract][Full Text] [Related]
8. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC.
Araújo LA; Junqueira DM; de Medeiros RM; Matte MC; Almeida SE
J Clin Virol; 2012 May; 54(1):6-10. PubMed ID: 22336085
[TBL] [Abstract][Full Text] [Related]
9. Antibody neutralization and escape by HIV-1.
Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
[TBL] [Abstract][Full Text] [Related]
11. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
[TBL] [Abstract][Full Text] [Related]
12. Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.
Quakkelaar ED; Bunnik EM; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Schuitemaker H
Virology; 2007 Jul; 363(2):447-53. PubMed ID: 17355886
[TBL] [Abstract][Full Text] [Related]
13. Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity.
Bunnik EM; Lobbrecht MS; van Nuenen AC; Schuitemaker H
Virology; 2010 Feb; 397(1):224-30. PubMed ID: 19945135
[TBL] [Abstract][Full Text] [Related]
14. Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease.
Song B; Cayabyab M; Phan N; Wang L; Axthelm MK; Letvin NL; Sodroski JG
Virology; 2004 Apr; 322(1):168-81. PubMed ID: 15063126
[TBL] [Abstract][Full Text] [Related]
15. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
[TBL] [Abstract][Full Text] [Related]
16. Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy.
Wang Q; Bi W; Zhu X; Li H; Qi Q; Yu F; Lu L; Jiang S
J Virol; 2015 Jul; 89(13):6960-4. PubMed ID: 25903343
[TBL] [Abstract][Full Text] [Related]
17. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity.
Scherer EM; Zwick MB; Teyton L; Burton DR
AIDS; 2007 Oct; 21(16):2131-9. PubMed ID: 18090039
[TBL] [Abstract][Full Text] [Related]
18. Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.
Bouvin-Pley M; Morgand M; Meyer L; Goujard C; Moreau A; Mouquet H; Nussenzweig M; Pace C; Ho D; Bjorkman PJ; Baty D; Chames P; Pancera M; Kwong PD; Poignard P; Barin F; Braibant M
J Virol; 2014 Dec; 88(23):13910-7. PubMed ID: 25231299
[TBL] [Abstract][Full Text] [Related]
19. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
[TBL] [Abstract][Full Text] [Related]
20. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
